| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Ginkgo Bioworks (NYSE: DNA) announced today that it has been awarded a contract through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to develop innovations that strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies (mAbs) to protect against and treat infection by filoviruses such as Ebola (EBOV) and Sudan Viruses (SUDV).
The project has a total contract value of up to $22.2 million and seeks to deploy these innovations to produce the anti-filovirus mAbs cocktail of 1C3 and 1C11, discovered and developed by Emory University.
Posted In: DNA
